These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study. Li JY; Dai Y; Sun XH; Ren HT; Shen DC; Yang XZ; Liu MS; Cui LY Brain Behav; 2023 May; 13(5):e2997. PubMed ID: 37070132 [TBL] [Abstract][Full Text] [Related]
46. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979 [TBL] [Abstract][Full Text] [Related]
47. Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. Wilke C; Pujol-Calderón F; Barro C; Stransky E; Blennow K; Michalak Z; Deuschle C; Jeromin A; Zetterberg H; Schüle R; Höglund K; Kuhle J; Synofzik M Clin Chem Lab Med; 2019 Sep; 57(10):1556-1564. PubMed ID: 31251725 [TBL] [Abstract][Full Text] [Related]
48. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression. Rabl M; Zullo L; Lewczuk P; Kornhuber J; Karikari TK; Blennow K; Zetterberg H; Bavato F; Quednow BB; Seifritz E; von Gunten A; Clark C; Popp J Alzheimers Res Ther; 2024 Jul; 16(1):165. PubMed ID: 39054505 [TBL] [Abstract][Full Text] [Related]
49. Plasma Amyloid-β, Total Tau, and Neurofilament Light Chain Across the Alzheimer's Disease Clinical Spectrum: A Population-Based Study. Dong Y; Hou T; Li Y; Liu R; Cong L; Liu K; Liu C; Han X; Ren Y; Tang S; Winblad B; Blennow K; Wang Y; Du Y; Qiu C J Alzheimers Dis; 2023; 96(2):845-858. PubMed ID: 37899059 [TBL] [Abstract][Full Text] [Related]
50. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D; Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532 [TBL] [Abstract][Full Text] [Related]
51. Cerebrospinal fluid neurofilament light chain and total-tau as biomarkers of neurodegeneration in Alzheimer's disease and frontotemporal dementia. Giuffrè GM; Quaranta D; Costantini EM; Citro S; Martellacci N; De Ninno G; Vita MG; Guglielmi V; Rossini PM; Calabresi P; Marra C Neurobiol Dis; 2023 Oct; 186():106267. PubMed ID: 37652185 [TBL] [Abstract][Full Text] [Related]
52. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745 [TBL] [Abstract][Full Text] [Related]
53. Neurofilament light as a biomarker of axonal degeneration in patients with mild cognitive impairment and Alzheimer's disease. Chen Y; Therriault J; Luo J; Ba M; Zhang H; Initiative ADN J Integr Neurosci; 2021 Dec; 20(4):861-870. PubMed ID: 34997710 [TBL] [Abstract][Full Text] [Related]